Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ovestin for Vulvar and Vaginal Atrophy
NCT04159493Phase 2Withdrawn
- Sponsor
- Aspen Pharmacare
- Start
- Jun 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in vulvovaginal atrophy (VVA) comparing Ovestin with Placebo (2 arms). Primary endpoints: Vaginal Maturation Index at 12 weeks, Vaginal pH at 12 weeks and 1 more. Planned start Jun 2021; status: withdrawn.
02
Drugs
estriol
03
Conditions
vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT04159493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159493.